Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Saniona AB ( (SE:SANION) ) has provided an update.
Saniona announced that its partner, Acadia Pharmaceuticals, will host an R&D Day to discuss its neurological and rare disease pipeline, including ACP-711, a compound originally developed by Saniona. This event highlights the progress of ACP-711, which Saniona outlicensed to Acadia, and underscores the potential impact on Saniona’s operations through potential milestone payments and royalties.
More about Saniona AB
Saniona is a clinical-stage biopharmaceutical company based in Copenhagen, focusing on neurological and psychiatric diseases. It has an internal pipeline that includes treatments for epilepsy and major depressive disorder, and strategic collaborations with Acadia Pharmaceuticals and Productos Medix. Saniona is listed on Nasdaq Stockholm Main Market.
Average Trading Volume: 690,744
Current Market Cap: SEK1.44B
For a thorough assessment of SANION stock, go to TipRanks’ Stock Analysis page.